This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Applied Clinical Trials Magazine Advises Clinical Trials To Put Patients First In New Peer-Reviewed Article

ISELIN, N.J., April 3, 2013 /PRNewswire/ -- Clinical trials are the cornerstone of getting biopharmaceuticals approved to treat diseases now and develop new medicines and knowledge for the future. Many people are unfamiliar with clinical trials until they or a loved one face a life-or-death disease diagnosis. Then the choices to treat their condition become more confusing and urgent. This is true even for professionals who work in and understand clinical trials. In Applied Clinical Trials magazine, Linda Strause, PhD, Executive Director & Head, Clinical Operations, Vical Inc., and Research Scientist & Founder, Institute of Palliative Medicine & San Diego Hospice IRB, discusses her personal experience when her husband, Randy, is diagnosed with glioblastoma, an incurable brain cancer.

"It's hard to imagine anyone better suited to navigating the clinical trial process than I was. I have a doctorate in neurophysiology and I am the executive director and head of clinical operations at a biotechnology company where I have been conducting oncology research for years and currently manage a Phase III melanoma trial," writes Strause.

Only 3% to 5% of cancer patients participate in clinical trials, while oncology drug development projects account for 31% of all clinical trial projects worldwide. Now on the other side of her experiences – which surround her husband's subsequent death – Strause offers advice for the industry to change clinical trials by putting patients at the center of the clinical research enterprise.

"While the movement for patient-centric healthcare is growing, it has only started to be recognized as a better way to conduct clinical trials," says Applied Clinical Trials Content Director Lisa Henderson. "The role of the patient is only going to grow in the next few years. While the content we offer is geared toward clinical trials professionals, and Linda's article offers concrete advice for those insiders, I believe the article can also help many others going through these difficult decisions."

For the full text of the article "Patient-First Approach to Improve Oncology Clinical Trials," visit on our web site

Contact: Lisa Henderson Editorial Director Email732-346-3080

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Applied Clinical Trials

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs